Pyodermatitis vegetans responding to rifampicin and clindamycin

Nuha Alfurayh, MBBS, Ahmed Alhumidi, MD, and Salim Alkeraye, MD
Riyadh, Saudi Arabia

Key words: clindamycin; inflammatory; neutrophilic; pyodermatitis; rifampicin.

INTRODUCTION
Pyodermatitis vegetans, or pyoderma vegetans (PDV), is a rare inflammatory cutaneous disease characterized by well-circumscribed, exudative vegetating plaques with elevated margins affecting the face, scalp, intertriginous regions, and, less often, the trunk and distal extremities.1-3 PDV is sometimes present in association with oral lesions termed, pyostomatitis vegetans (PSV).2,3 PDV is known to be correlated with gastrointestinal disorders, particularly inflammatory bowel disease (IBD).4,6 Other diseases reported in association with PDV include T-cell lymphoma, chronic myeloid leukemia, liver diseases, malnutrition, HIV infection, and primary immunodeficiency disorders.5 Multiple topical and systemic medications have been described to treat PDV with varying efficacies.6 We report on a case of PDV in a patient with Crohn’s disease treated with a combination of rifampicin and clindamycin with good results.

CASE REPORT
A 35-year-old man known to have Crohn’s disease for 13 years presented to the dermatology clinic with purulent skin lesions that had started 2 months previously. The patient had undergone a total colectomy 3 years earlier due to his recalcitrant Crohn’s disease that was resistant to multiple therapies, including infliximab and adalimumab. He was not taking any medications at the time of presentation.

Skin examination found multiple well-defined erythematous and vegetative plaques with dark brown, raised borders and overlying yellow crusts along with multiple hypopigmented scars over the trunk (Fig 1), axillae, inguinal folds, and lower limbs. No mucosal, scalp, or nail lesions were observed.

Histopathologic studies found extensive neutrophilic infiltrate in the stratum corneum. The epidermis showed psoriasiform hyperplasia with scattered neutrophils. The papillary dermis exhibited edema and dilated blood vessels. The reticular dermis showed infiltration of a mix of inflammatory cells, including many neutrophils, scattered lymphocytes, and eosinophils, over a background of fibrosis and granulation tissue (Fig 2). Direct immunofluorescence studies were negative. Bacterial culture found a growth of Staphylococcus aureus. Fungal and mycobacterial cultures were negative. Results of basic blood tests including complete blood count, hemoglobin level, liver function, and renal profile were unremarkable.

Our initial impression was an atypical hidradenitis suppurativa (HS) or PDV. Therefore, the patient was treated with a combination of clindamycin and rifampicin, at a dose of 300 mg, twice a day each. Three weeks into the treatment course, the diagnosis of PDV was supported by the histopathology results, which showed neutrophilic infiltration and areas of granulation tissue in the dermis. However, the patient was already showing a good response to the combined antibiotic treatment. After completing 6 weeks of clindamycin and rifampicin treatment, all lesions had regressed and were completely asymptomatic (Fig 3). The patient remained disease free for the next 3 months. However, the lesions

---

From the Departments of Dermatologya and Pathology,b College of Medicine, King Saud University.

Funding sources: None.

Conflicts of interest: None disclosed.

Correspondence to: Nuha Alfurayh, MBBS, Department of Dermatology, College of Medicine, King Saud University, Riyadh, Saudi Arabia. E-mail: Nuha.alfurayh@gmail.com.

JAAD Case Reports 2019;5:1078-80.
2352-5126
© 2019 by the American Academy of Dermatology, Inc. Published by Elsevier, Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
https://doi.org/10.1016/j.jdcr.2019.10.006

1078
recurred 4 months later (Fig 4), and a treatment with 0.5 mg/kg of prednisone daily rapidly controlled the disease. The patient is currently in a clinical remission on a daily dose of 10 mg of prednisone.

**DISCUSSION**

PDV is a rare inflammatory neutrophilic dermatosis that was initially described in 1898 by Hallopeau. Previous reports have indicated that PDV is frequently associated with IBD in 70% of cases, and up to 100% in a recent cohort study. PDV commonly affects adults in the third decade of life with a male/female ratio of 3:1. The etiology of PDV is still unknown. However, variable immunologic and microbial factors have been proposed.

Cutaneous lesions are characterized by erythematous vesiculopustules that coalesce to form exudative vegetating plaques commonly involving the scalp, axilla, and groin. Other areas reported to
be affected include the face, trunk, and extremities.\textsuperscript{1-3} HS has also been reported in association with IBD.\textsuperscript{11} In our case, the initial observation of the lesions in intertriginous folds raised the possibility of atypical HS. However, the histologic findings were not supportive of this diagnosis.

The histopathologic features of PDV include epidermal hyperplasia containing large amounts of neutrophils and eosinophils. Acanthosis, acantholysis, and suprabasilar clefts can also be observed with PDV. In the dermis, dense inflammatory infiltrates with various inflammatory cells, including eosinophils, neutrophils, lymphocytes, and plasmocytes, are observed. Immunofluorescence studies usually show negative results.\textsuperscript{3,12} Fungal, viral, bacterial, and mycobacterial cultures are typically negative, but a secondary bacterial infection with at least a single pathogenic bacteria, such as \textit{S} aureus, \textit{β}-hemolytic streptococci, \textit{Pseudomonas aeruginosa}, or \textit{Escherichia coli} anaerobes, is usually identified.\textsuperscript{1} In our case, the observed growth of \textit{S} aureus is most likely caused by a secondary bacterial infection.

Multiple previous studies have considered PDV as a clinical marker for IBD activity and recommended that a total/subtotal colectomy is a therapeutic option for complete remission of symptoms.\textsuperscript{3,6,13} However, in 2015, Uzunçakmak et al\textsuperscript{9} reported on a case of PDV developed shortly after a total colectomy and discontinuation of systemic corticosteroid.\textsuperscript{9} Here we report a first presentation of PDV 3 years after total colectomy in a patient with Crohn’s disease.

Previous studies have demonstrated that treating PDV is primarily accomplished by controlling the underlying IBD. To date, there is no standardized treatment for PDV. A variety of pharmacologic therapies have been suggested. Topical or systemic corticosteroids were recommended as a first-line therapy. Other reported therapeutic agents include dapsone, sulfasalazine, tacrolimus, azathioprine, cyclosporine, isotretinoin, infliximab, and methotrexate.\textsuperscript{15} For patients with positive bacterial cultures, appropriate antibiotics were added as a conjunctive therapy. In spite of the morphologic similarities of PDV to HS, the combined antibiotic therapy of rifampicin and clindamycin is not a treatment that is suggested for PDV. Here we report a good response of PDV to a combination of oral clindamycin and rifampicin.

REFERENCES
1. Matias FD, Rosa DJ, Carvalho MT, Castaño MC. Pyodermatitis-pyostomatitis vegetans: case report and review of medical literature. \textit{An Bras Dermatol}. 2011;86:137-140.
2. Storwick GS, Prihoda MB, Fulton RJ, Wood WS. Pyodermatitis-pyostomatitis vegetans: a specific marker for inflammatory bowel disease. \textit{J Am Acad Dermatol}. 1994;31:336-341.
3. Dodd EM, Howard JR, Dulaney ED, et al. Pyodermatitis pyostomatitis vegetans associated with asymptomatic inflammatory bowel disease. \textit{Int J Dermatol}. 2017;56:1457-1459.
4. Thrash B, Patel M, Shah KR, et al. Cutaneous manifestations of gastrointestinal disease: part II. \textit{J Am Acad Dermatol}. 2013;68:211.e1-33.
5. Adiisen E, Tezel F, Gürer MA. Pyoderma vegetans: a case for discussion. \textit{Acta Derm Venereol}. 2009;89:186-188.
6. Clark LG, Tolkachjov SN, Bridges AG, Camilleri MJ. Pyostomatitis vegetans (PSV)-pyodermatitis vegetans (PDV): a clinicopathologic study of 7 cases at a tertiary referral center. \textit{J Am Acad Dermatol}. 2016;75:578-594.
7. Hallopeau H. Pyodermitite vegetante, ihre Beziehungen zur dermatitis herpetiformis und dem pemphigus vegetans. \textit{Arch Dermatol Syph}. 1898;43:289-306.
8. Kim TH, Kim SC. Pyodermatitis-pyostomatitis vegetans associated with Crohn’s disease. \textit{Ann Dermatol}. 2015;27:624-625.
9. Uzunçakmak TK, Akdeniz N, Karadağ AS, Çobanoğlu B. Pyodermatitis vegetans after total colectomy. \textit{Indian Dermatol Online J}. 2015;6:59-61.
10. Marzano AV, Borghi A, Stadnicki A, et al. Cutaneous manifestations in patients with inflammatory bowel diseases: pathophysiology, clinical features, and therapy. \textit{Inflamm Bowel Dis}. 2013;20:213-227.
11. Chen WT, Chi CC. Association of hidradenitis suppurativa with inflammatory bowel disease: a systematic review and meta-analysis. \textit{JAMA Dermatol}. 2019. \texttt{https://doi.org/10.1001/jamadermatol.2019.0891}.
12. Wang H, Qiao S, Zhang X, Liu C. A case of pyodermatitis-pyostomatitis vegetans. \textit{Am J Med Sci}. 2013;345:168-171.
13. Pellicer Z, Santiago JM, Rodriguez A, et al. Management of cutaneous disorders related to inflammatory bowel disease. \textit{Ann Gastroenterol}. 2012;25:21-26.